Wan Y D, Zang Q Z, Wang J S
Sichuan Institute of Chinese Materia Medica, Chongqing.
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1992;10(4):290-4.
The pharmacological and clinical effects of gelatin capsule of Artemisia annua (GCAA) were investigated. The results revealed that the LD50 was 162.5 +/- 10.1g (crude drug)/kg and ED50 was 11.9 +/- 2.4g (crude drug) for clearance of parasitemia in mice infected with Plasmodium berghei therapeutic index being 13.6, which was 3.5 times more than that of artemisinin. The cure rate of COEA for Plasmodium berghei and P. vivax infections was 100%, as well as just like that of the extract tablets of Artemisia annua and chloroquine. This formulation was found to be better than chloroquine in fever subsidence and disappearance of malarial symptoms, while the recrudescence rate was still high, the latter could be inhibited by increasing therapeutic course or daily dosing time or by combination with primaquine.
对青蒿明胶胶囊(GCAA)的药理和临床效果进行了研究。结果显示,对于感染伯氏疟原虫的小鼠,清除疟原虫血症的半数致死量(LD50)为162.5±10.1克(生药)/千克,半数有效量(ED50)为11.9±2.4克(生药),治疗指数为13.6,是青蒿素的3.5倍。GCAA对伯氏疟原虫和间日疟原虫感染的治愈率为100%,与青蒿素片和氯喹相同。发现该制剂在退热和疟疾症状消失方面优于氯喹,然而复发率仍然较高,通过增加疗程或每日给药次数或与伯氨喹联合使用可抑制后者。